Table 2.
Baseline characteristics of cardiometabolic parameters of the patients receiving dapagliflozin and vildagliptin
| Total (n = 49) | Dapagliflozin (n = 25) | Vildagliptin (n = 24) | P value | |
|---|---|---|---|---|
| Body weight (kg) | 63.06 ± 11.93 | 63.70 ± 10.44 | 62.38 ± 13.50 | .705 |
| BMI (kg/m2) | 25.28 ± 3.06 | 25.63 ± 3.00 | 24.90 ± 3.158 | .408 |
| Waist circumference (cm) | 90.57 ± 9.89 | 89.86 ± 8.27 | 91.46 ± 11.77 | .610 |
| Waist–hip ratio | 0.96 ± 0.08 | 0.95 ± 0.06 | 0.97 ± 0.10 | .542 |
| Systolic blood pressure (mmHg) | 124.50 ± 17.88 | 124.75 ± 20.63 | 124.24 ± 14.92 | .921 |
| Diastolic blood pressure (mmHg) | 67.97 ± 8.66 | 67.39 ± 7.58 | 68.57 ± 9.79 | .639 |
| Fasting plasma glucose (mg/dL) | 143.49 ± 35.20 | 148.56 ± 42.29 | 138.21 ± 25.75 | .305 |
| HbA1c (%) | 8.21 ± 1.27 | 8.17 ± 1.41 | 8.25 ± 1.13 | .811 |
| Total cholesterol (mg/dL) | 153.10 ± 35.73 | 144.86 ± 33.23 | 162.15 ± 36.99 | .121 |
| LDL cholesterol (mg/dL) | 91.74 ± 37.20 | 82.20 ± 30.45 | 101.27 ± 41.42 | .090 |
| HDL cholesterol (mg/dL) | 45.88 ± 13.70 | 47.10 ± 16.75 | 44.67 ± 10.05 | .573 |
| Triglyceride (mg/dL) | 168.07 ± 65.43 | 163.00 ± 66.09 | 173.14 ± 65.99 | .621 |
| Creatinine (mg/dL) | 1.05 ± 0.34 | 1.01 ± 0.29 | 1.10 ± 0.39 | .378 |
| eGFR (mL/min/1.73m2) | 69.99 ± 20.65 | 72.11 ± 19.59 | 67.79 ± 21.90 | .471 |
| NT‐proBNP (pg/mL) | 672.18 ± 1359.04 | 399.94 ± 493.10 | 955.76 ± 1853.75 | .154 |
| hs‐TnT (pg/mL) | 15.80 ± 12.29 | 14.54 ± 9.46 | 17.10 ± 14.78 | .477 |
| hs‐CRP (mg/L) | 1.52 ± 1.75 | 1.55 ± 1.78 | 1.48 ± 1.79 | .913 |
| Left ventricular ejection fraction (%) | 57.07 ± 14.64 | 57.18 ± 16.28 | 56.95 ± 13.06 | .957 |
All data are means ± standard deviation. BMI, body mass index; HbA1c, haemoglobin A1c; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; hs‐TnT, high‐sensitivity troponin T; hs‐CRP, high‐sensitivity C‐reactive protein; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, how‐density lipoprotein.